On Tuesday, Dr Reddy’s Laboratories announced in an investor call that the company aims to have about “15 GLP-1 drugs" to ...

Brand-heavy companies such as Mankind Pharma, Sun Pharma, Torrent Pharmaceuticals and Eris Lifesciences are expected to ...

The Subject Expert Committee (SEC), which advises the national drug regulator on approval of new drugs and clinical trials, has recommended grant of market authorisation for Dr Reddy's Laboratories' ...

In its June quarter results, Oil India had exceeded analysts’ estimates in terms of consolidated net profit. The profit after ...

Indian drugmaker Alembic Pharmaceuticals reported a smaller-than-expected rise in second-quarter profit on Thursday, hurt by a slowdown in the U.S. market amid pricing pressure. The ...

Erez Israeli, CEO of Dr Reddy's Laboratories highlights the moves he is undertaking to position his company as a market ...

Stay updated with the Dr Reddys Stock Liveblog, your one-stop destination for real-time information and analysis of a leading stock. Explore the latest updates on Dr Reddys stock, including: Last ...

RDY misses on earnings but beats on revenues in the fiscal second quarter. The bottom line suffers due to a one-time ...

Dr. Reddy’s (DRRD) Q2FY25 EBITDA was largely in line with our estimate. The base business margins and US sales ex of ...

Motilal Oswal recommended Neutral rating on Dr Reddys Laboratories with a target price of Rs 1390 in its research report ...

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Dr Reddy’s Laboratories (RDY – Research Report), ...

Dr Reddy's Laboratories has reported a decline of 9.36 per cent in net profit at Rs. 1,341.5 crore on a consolidated basis during the second quarter ended September 30, 2024, as compared to Rs. 1,480 ...